Aarvik’s mission is to develop
powerful innovations in oncology
therapeutics via tetravalent,
multifunctional antibody platforms
At Aarvik, we believe improving clinical efficacy and lowering the minimum efficacious dose (MED), while maintaining or improving the maximum tolerated dose (MTD), is a powerful approach to increasing the therapeutic index of ADCs.
Our unique and comprehensive MUTTA™ ADC platform can unlock a large number of tumor antigen targets with low copy numbers, unsuccessfully pursued so far.